Atrial Fibrillation and
Risk of Stroke

AF and the Left Atrial Appendage

Because the upper chambers of the heart (atria) are unable to contract properly in patients with atrial fibrillation (AF), clots are able to form. A common site for clot formation is the left atrial appendage (LAA), which is attached to the left atrium. More than 90% of strokes in people with non-valvular AF (NVAF) are caused by blood clots formed in the LAA.1,2

AF and Stroke are Often Connected

90% are caused by clots
formed in the LAA2
5X higher risk for
patients with AF3
1 in 7 are
caused by AF4
Characteristics of strokes caused by AF:3

AF and the Challenges of Medication

Many patients at risk of stroke want an alternative to oral anticoagulants (OACs, for example, warfarin) and non-vitamin K oral anticoagulants (NOACs).5

40% do not take OACs
(NOACs or warfarin)5,7
25% discontinuation
rate (NOACs)5,8

CHALLENGES OF NOACS AND WARFARIN INCLUDE:5,7-8

  • Significant bleeding risks
  • Significant non-compliance rates
  • Regular INR monitoring (warfarin)
  • Food and drug interaction issues (warfarin)
  • Complicates surgical procedures
  • High cost (NOACs)

LAA Occlusion is an Alternative to LONG-TERM Medication for reducing risk of stroke

Surgery to remove or tie-off the LAA is highly invasive.

  • Typically reserved for patients undergoing cardiac surgery for concomitant conditions.
  • Complete closure rates range from 0% to 100%.5

Transcatheter occlusion of the LAA is minimally-invasive.

  • Closure rates are 98.9% with the Amplatzer Amulet LAA Occluder.6

Reducing stroke risk for AF patients

Abbott offers a way to permanently close the left atrial appendage.
 

Amplatzer™ AMULET™ LAA Occluder

MAT-2111178 v1.0 | Item approved for U.S. use only

References
  1. Yaghi S, Song C, Gray WA, et al. Left atrial appendage function and stroke risk, Stroke 2015;46:3554-3559.
    www.ahajournals.org/doi/10.1161/strokeaha.115.011273. Accessed April 21, 2021
  2. Blackshear JL., Odell JA. Annals of Thoracic Surg. 1996; 61: 755-759.
  3. Fuster V, Rydén LE, Cannom DS, et al. Crijns, (). ACC/AHA/ESC Practice Guidelines. Circulation. 2006;114:700-752
  4. Heart Rhythm Society. (2019). Complications from Atrial Fibrillation. Accessed April 21, 2021.
  5. Suradi HS, et al. Left atrial appendage closure: outcomes and challenges. Neth Heart J. 2017;25:143-151. doi: 10.1007/s12471-016-0929-0.
  6. Amplatzer Amulet LAA Occluder IFU, 2021.
  7. Kakkar AK, et al. Risk profiles and antithrombotic treatment of patients newly diagnosed with atrial fibrillation at risk of stroke: perspectives from the international, observational, prospective GARFIELD registry. PLOS ONE. 8(5):e63479. doi.org/10.1371/journal.pone.0063479.
  8. Baman JR, et al. Percutaneous left atrial appendage occlusion in the prevention of stroke in atrial fibrillation: a systematic review. Heart Failure Rev. 2018;23:191–208. doi.org/10.1007/s10741-018-9681-4.

 

Important safety information

AMPLATZER™ AMULET™ LEFT ATRIAL APPENDAGE OCCLUDER
INDICATION FOR USE

The Amplatzer™ Amulet™ Left Atrial Appendage Occluder is a percutaneous transcatheter device intended to reduce the risk of thrombus embolization from the left atrial appendage (LAA) in patients who have nonvalvular atrial fibrillation and who are at increased risk for stroke and systemic embolism based on CHADS2 or CHA2DS2-VASc scores, are suitable for short term anticoagulation therapy, and have appropriate rationale to seek a non-pharmacologic alternative to oral anticoagulation, taking into consideration the safety and effectiveness of the device.

CONTRAINDICATIONS

The Amplatzer™ Amulet™ Left Atrial Appendage (LAA) Occluder is contraindicated for patients:

  • with the presence of intracardiac thrombus,
  • with active endocarditis or other infections producing bacteremia.
  • where placement of the device would interfere with any intracardiac or intravascular structures.

WARNINGS

  •  If the device is retracted while it is in the sheath, the device and the sheath must both be removed and replaced. Failure to replace both the device and the sheath may result in sheath and/or device malfunction.
  • If the device is retracted farther than the radiopaque markers (fully recaptured), the device and the sheath must both be removed and replaced. Failure to replace both the device and the sheath may result in sheath and/or device malfunction.
  • Physicians must be prepared to deal with urgent situations, such as pericardial effusion or device embolization, which can require removal of the device.
  • This device should be used only by physicians who are trained in standard transcatheter techniques. The physician should determine which patients are candidates for procedures that use this device.
  • Late pericardial effusion events were observed in the clinical study. The use of post-procedure anticoagulation therapy may be associated with an increased potential for a late pericardial effusion. Physicians should monitor for signs and symptoms of pericardial effusion and obtain appropriate imaging when indicated. Physicians should also consider routine echocardiography to screen for pericardial effusion.
  • Remove embolized devices. Do not remove an embolized device unless the device is fully captured inside a sheath.
  • The Amplatzer™ Amulet™ device contains a nickeltitanium alloy, which is generally considered safe. However, in vitro testing has demonstrated that nickel is released from this device for a minimum of 120 days. Patients who are allergic to nickel may have an allergic reaction to this device, especially those with a history of metal allergies. Certain allergic reactions can be serious; patients should be instructed to seek medical assistance immediately if they suspect they are experiencing an allergic reaction. Symptoms may include difficulty in breathing or swelling of the face or throat. While data are currently limited, it is possible that some patients may develop an allergy to nickel if this device is implanted.
  • Do not use this device if the sterile package is open or damaged.
  • The device was sterilized with ethylene oxide and is for single use only. Do not reuse or resterilize this device. Attempts to resterilize this device can cause a malfunction, insufficient sterilization, or harm to the patient.
  • Use on or before the expiration date that is printed on the product packaging label.

PRECAUTIONS

  • The physician should exercise clinical judgment in situations that involve the use of antithrombotic drugs before, during, and/or after the use of this device.
  • The physician should exercise caution if implanting a device in a patient who has an implantable cardioverter defibrillator (ICD) or pacemaker leads.
  • The physician should have the guidewire in the left upper pulmonary vein when making exchanges in the left atrium.
  • Ensure that the vasculature is adequate for the sheath size being selected.
  • The physician should exercise caution if performing ablation at or near the implant site after the device is implanted.
  • Use standard interventional cardiovascular catheterization techniques when using Amplatzer™ products.
  • Use in specific populations
    • Pregnancy – Minimize the radiation exposure to the fetus and the mother.
    • Nursing mothers – There has been no quantitative assessment for the presence of leachables in breast milk.

MRI SAFETY INFORMATION

Non-clinical testing has demonstrated that the Amplatzer™ Amulet™ Left Atrial Appendage Occluder device is MR Conditional. A patient with the Amplatzer™Amulet™ device can be safely scanned in an MR system under the following conditions:

  • Static magnetic fields of 1.5 Tesla (1.5T) and 3.0 Tesla (3.0T)
  • Maximum spatial gradient field of 19 T/m (1900 G/cm)
  • Maximum MR system reported, whole-body averaged specific absorption rate (SAR) of 2.0 W/kg (normal operating mode)

Under the scan conditions defined above, the device is expected to produce a maximum temperature rise of less than or equal to 4°C after 15 minutes of continuous scanning.

In non-clinical testing, the image artifact caused by the device extends radially up to 20 mm from the device when imaged with a gradient echo pulse sequence in a 3.0T MR system.

POTENTIAL ADVERSE EVENTS

Potential adverse events associated with the device or implant procedure include, but are not limited to, the following:

  • Air embolism
  • Airway trauma
  • Allergic reaction
  • Anemia
  • Anesthesia reaction (nausea, vasovagal reaction, confusion/altered mental status or other)
  • Arrhythmia
  • Atrial septal defect
  • Bleeding
  • Cardiac arrest
  • Cardiac tamponade
  • Chest pain/discomfort
  • Congestive heart failure
  • Death
  • Device embolization
  • Device erosion
  • Device malfunction
  • Device malposition
  • Device migration
  • Device-related thrombus
  • Fever
  • Hematuria
  • Hypertension/hypotension
  • Infection
  • Multi-organ failure
  • Myocardial infarction
  • Perforation
  • Pericardial effusion
  • Pleural effusion
  • Renal failure/dysfunction
  • Respiratory failure
  • Seizure
  • Significant residual flow
  • Stroke
  • Thrombocytopenia
  • Thromboembolism: peripheral and pulmonary
  • Thrombus formation 
  • Transient ischemic attack 
  • Valvular regurgitation/insufficiency
  • Vascular access site injury (hematoma, pseudoaneurysm, arteriovenous fistula, groin pain or other)
  • Vessel trauma/injury

This site uses cookies to improve your experience.

To find out more please read our Privacy and Cookies policy.

Ok

SIGN UP

Receive updates from Abbott Structural Heart

YOU ARE ABOUT TO ENTER AN ABBOTT COUNTRY OR REGION SPECIFIC WEBSITE.

Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of the product that are not approved in other countries or regions.

YOU ARE ABOUT TO LEAVE
www.structural­heart­solutions.com

You are now leaving www.structuralheartsolutions.com. Abbott is not responsible for any content published on the third-party website you are about to enter. Abbott has not reviewed and does not endorse any information presented on third-party websites.